Women's Health Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

TMR's report on the global women's health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global women's health market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global women's health market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the women's health market.

Market Snapshot
Market Value in 2023	US$ 77.8 Bn
Market Value in 2031	US$ 130.9 Bn
CAGR	5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global women's health market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global women's health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global women's health market.

The report delves into the competitive landscape of the global women's health market. Key players operating in the global women's health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global women's health market profiled in this report.

Key Questions Answered in Global women's health Market Report:

What is the sales/revenue generated by women's health across all regions during the forecast period?
What are the opportunities in the global women's health market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Women's Health Market - Research Objectives and Research Approach

The comprehensive report on the global women's health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global women's health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global women's health market.

Product Code: TMRGL214

1. Executive Summary

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Women's Health Market

4. Market Overview

4.1. Market Segmentation
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Women's Health Market Analysis and Forecast, 2023-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. List of Common Health Issues Among Women
5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
5.4. COVID-19 Pandemic Impact on Industry

6. Women's Health Market Analysis and Forecast, by Treatment Type

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2023-2031
- 6.3.1. Hormonal Treatment
  - 6.3.1.1. Estrogen Therapy
  - 6.3.1.2. Progestin Therapy
  - 6.3.1.3. Combination Therapy
  - 6.3.1.4. Thyroid Replacement Therapy
  - 6.3.1.5. Parathyroid Hormone Therapy
  - 6.3.1.6. Others
- 6.3.2. Non-Hormonal Treatment
  - 6.3.2.1. Targeted Therapy Drugs
  - 6.3.2.2. Antibiotics
  - 6.3.2.3. Bisphosphonates
  - 6.3.2.4. Others
6.4. Market Attractiveness, by Treatment Type

7. Global Women's Health Market Analysis and Forecast, by Disease Indication

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2023-2031
- 7.3.1. Cancer
  - 7.3.1.1. Breast Cancer
  - 7.3.1.2. Cervical Cancer
  - 7.3.1.3. Ovarian Cancer
- 7.3.2. Hypothyroidism
- 7.3.3. Post-Menopausal Syndrome
- 7.3.4. Osteoporosis
- 7.3.5. Contraception
- 7.3.6. Uterine Fibroid
- 7.3.7. Urinary Tract Infection
- 7.3.8. Others
7.4. Market Attractiveness, by Disease Indication

8. Global Women's Health Market Analysis and Forecast, by Region

8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023-2031
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

9. North America Women's Health Market Analysis and Forecast

9.1. Introduction
- 9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2023-2031
- 9.2.1. Hormonal Treatment
  - 9.2.1.1. Estrogen Therapy
  - 9.2.1.2. Progestin Therapy
  - 9.2.1.3. Combination Therapy
  - 9.2.1.4. Thyroid Replacement Therapy
  - 9.2.1.5. Parathyroid Hormone Therapy
  - 9.2.1.6. Others
- 9.2.2. Non-Hormonal Treatment
  - 9.2.2.1. Targeted Therapy Drugs
  - 9.2.2.2. Antibiotics
  - 9.2.2.3. Bisphosphonates
  - 9.2.2.4. Others
9.3. Market Value Forecast, by Disease Indication, 2023-2031
- 9.3.1. Cancer
  - 9.3.1.1. Breast Cancer
  - 9.3.1.2. Cervical Cancer
  - 9.3.1.3. Ovarian Cancer
- 9.3.2. Hypothyroidism
- 9.3.3. Post-Menopausal Syndrome
- 9.3.4. Osteoporosis
- 9.3.5. Contraception
- 9.3.6. Uterine Fibroid
- 9.3.7. Urinary Tract Infection
- 9.3.8. Others
9.4. Market Value Forecast, by Country, 2023-2031
- 9.4.1. U.S.
- 9.4.2. Canada
9.5. Market Attractiveness Analysis

10. Europe Women's Health Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2023-2031
- 10.2.1. Hormonal Treatment
  - 10.2.1.1. Estrogen Therapy
  - 10.2.1.2. Progestin Therapy
  - 10.2.1.3. Combination Therapy
  - 10.2.1.4. Thyroid Replacement Therapy
  - 10.2.1.5. Parathyroid Hormone Therapy
  - 10.2.1.6. Others
- 10.2.2. Non-Hormonal Treatment
  - 10.2.2.1. Targeted Therapy Drugs
  - 10.2.2.2. Antibiotics
  - 10.2.2.3. Bisphosphonates
  - 10.2.2.4. Others
10.3. Market Value Forecast, by Disease Indication, 2023-2031
- 10.3.1. Cancer
  - 10.3.1.1. Breast Cancer
  - 10.3.1.2. Cervical Cancer
  - 10.3.1.3. Ovarian Cancer
- 10.3.2. Hypothyroidism
- 10.3.3. Post-Menopausal Syndrome
- 10.3.4. Osteoporosis
- 10.3.5. Contraception
- 10.3.6. Uterine Fibroid
- 10.3.7. Urinary Tract Infection
- 10.3.8. Others
10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis

11. Asia Pacific Women's Health Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2023-2031
- 11.2.1. Hormonal Treatment
  - 11.2.1.1. Estrogen Therapy
  - 11.2.1.2. Progestin Therapy
  - 11.2.1.3. Combination Therapy
  - 11.2.1.4. Thyroid Replacement Therapy
  - 11.2.1.5. Parathyroid Hormone Therapy
  - 11.2.1.6. Others
- 11.2.2. Non-Hormonal Treatment
  - 11.2.2.1. Targeted Therapy Drugs
  - 11.2.2.2. Antibiotics
  - 11.2.2.3. Bisphosphonates
  - 11.2.2.4. Others
11.3. Market Value Forecast, by Disease Indication, 2023-2031
- 11.3.1. Cancer
  - 11.3.1.1. Breast Cancer
  - 11.3.1.2. Cervical Cancer
  - 11.3.1.3. Ovarian Cancer
- 11.3.2. Hypothyroidism
- 11.3.3. Post-Menopausal Syndrome
- 11.3.4. Osteoporosis
- 11.3.5. Contraception
- 11.3.6. Uterine Fibroid
- 11.3.7. Urinary Tract Infection
- 11.3.8. Others
11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
- 11.5.1. By Treatment Type
- 11.5.2. By Disease Indication
- 11.5.3. By Country/Sub-region

12. Latin America Women's Health Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2023-2031
- 12.2.1. Hormonal Treatment
  - 12.2.1.1. Estrogen Therapy
  - 12.2.1.2. Progestin Therapy
  - 12.2.1.3. Combination Therapy
  - 12.2.1.4. Thyroid Replacement Therapy
  - 12.2.1.5. Parathyroid Hormone Therapy
  - 12.2.1.6. Others
- 12.2.2. Non-Hormonal Treatment
  - 12.2.2.1. Targeted Therapy Drugs
  - 12.2.2.2. Antibiotics
  - 12.2.2.3. Bisphosphonates
  - 12.2.2.4. Others
12.3. Market Value Forecast, by Disease Indication, 2023-2031
- 12.3.1. Cancer
  - 12.3.1.1. Breast Cancer
  - 12.3.1.2. Cervical Cancer
  - 12.3.1.3. Ovarian Cancer
- 12.3.2. Hypothyroidism
- 12.3.3. Post-Menopausal Syndrome
- 12.3.4. Osteoporosis
- 12.3.5. Contraception
- 12.3.6. Uterine Fibroid
- 12.3.7. Urinary Tract Infection
- 12.3.8. Others
12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
- 12.5.1. By Treatment Type
- 12.5.2. By Disease Indication
- 12.5.3. By Country/Sub-region

13. Middle East & Africa Women's Health Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2023-2031
- 13.2.1. Hormonal Treatment
  - 13.2.1.1. Estrogen Therapy
  - 13.2.1.2. Progestin Therapy
  - 13.2.1.3. Combination Therapy
  - 13.2.1.4. Thyroid Replacement Therapy
  - 13.2.1.5. Parathyroid Hormone Therapy
  - 13.2.1.6. Others
- 13.2.2. Non-Hormonal Treatment
  - 13.2.2.1. Targeted Therapy Drugs
  - 13.2.2.2. Antibiotics
  - 13.2.2.3. Bisphosphonates
  - 13.2.2.4. Others
13.3. Market Value Forecast, by Disease Indication, 2023-2031
- 13.3.1. Cancer
  - 13.3.1.1. Breast Cancer
  - 13.3.1.2. Cervical Cancer
  - 13.3.1.3. Ovarian Cancer
- 13.3.2. Hypothyroidism
- 13.3.3. Post-Menopausal Syndrome
- 13.3.4. Osteoporosis
- 13.3.5. Contraception
- 13.3.6. Uterine Fibroid
- 13.3.7. Urinary Tract Infection
- 13.3.8. Others
13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
- 13.5.1. By Treatment Type
- 13.5.2. By Disease Indication
- 13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
- 14.3.1. Eli Lilly and Company
  - 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.1.2. Product Portfolio
  - 14.3.1.3. Financial Overview
  - 14.3.1.4. SWOT Analysis
  - 14.3.1.5. Strategic Overview
- 14.3.2. Novartis AG
  - 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.2.2. Product Portfolio
  - 14.3.2.3. Financial Overview
  - 14.3.2.4. SWOT Analysis
  - 14.3.2.5. Strategic Overview
- 14.3.3. Pfizer, Inc.
  - 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.3.2. Product Portfolio
  - 14.3.3.3. Financial Overview
  - 14.3.3.4. SWOT Analysis
  - 14.3.3.5. Strategic Overview
- 14.3.4. Merck & Co., Inc.
  - 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.4.2. Product Portfolio
  - 14.3.4.3. Financial Overview
  - 14.3.4.4. SWOT Analysis
  - 14.3.4.5. Strategic Overview
- 14.3.5. Novo Nordisk A/S
  - 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.5.2. Product Portfolio
  - 14.3.5.3. Financial Overview
  - 14.3.5.4. SWOT Analysis
  - 14.3.5.5. Strategic Overview
- 14.3.6. Amgen Inc.
  - 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.6.2. Product Portfolio
  - 14.3.6.3. Financial Overview
  - 14.3.6.4. SWOT Analysis
  - 14.3.6.5. Strategic Overview
- 14.3.7. AstraZeneca
  - 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.7.2. Product Portfolio
  - 14.3.7.3. Financial Overview
  - 14.3.7.4. SWOT Analysis
  - 14.3.7.5. Strategic Overview
- 14.3.8. F. Hoffmann-La Roche Ltd
  - 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.8.2. Product Portfolio
  - 14.3.8.3. Financial Overview
  - 14.3.8.4. SWOT Analysis
  - 14.3.8.5. Strategic Overview
- 14.3.9. Sanofi
  - 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.9.2. Product Portfolio
  - 14.3.9.3. Financial Overview
  - 14.3.9.4. SWOT Analysis
  - 14.3.9.5. Strategic Overview
- 14.3.10. Allergan Plc.
  - 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.10.2. Product Portfolio
  - 14.3.10.3. Financial Overview
  - 14.3.10.4. SWOT Analysis
  - 14.3.10.5. Strategic Overview
- 14.3.11. GlaxoSmithKline plc
  - 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.11.2. Product Portfolio
  - 14.3.11.3. Financial Overview
  - 14.3.11.4. SWOT Analysis
  - 14.3.11.5. Strategic Overview
- 14.3.12. Lupin Pharmaceuticals, Inc.
  - 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.12.2. Product Portfolio
  - 14.3.12.3. Financial Overview
  - 14.3.12.4. SWOT Analysis
  - 14.3.12.5. Strategic Overview

Product Code: TMRGL214

List of Tables

Table 01: Global Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 02: Global Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
Table 03: Global Women's Health Market Value (US$ Mn) Forecast, by Region, 2023-2031
Table 04: North America Women's Health Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 05: North America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 06: North America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
Table 07: Europe Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 08: Europe Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 09: Europe Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
Table 10: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 11: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 12: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
Table 13: Latin America Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 14: Latin America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 15: Latin America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
Table 16: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 17: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
Table 18: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

List of Figures

Figure 01: Global Women's Health Market Value (US$ Mn) Forecast, 2023-2031
Figure 02: Global Women's Health Market Value Share, by Treatment Type, 2022
Figure 03: Global Women's Health Market Value Share, by Disease Indication, 2022
Figure 04: Global Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 05: Global Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 06: Global Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 07: Global Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
Figure 08: Global Women's Health Market Value Share Analysis, by Region, 2022 and 2031
Figure 09: Global Women's Health Market Attractiveness Analysis, by Region, 2023-2031
Figure 10: North America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
Figure 11: North America Women's Health Market Value Share Analysis, by Country, 2022 and 2031
Figure 12: North America Women's Health Market Attractiveness Analysis, by Country, 2023-2031
Figure 13: North America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 14: North America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 15: North America Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 16: North America Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
Figure 17: Europe Women's Health Market Value (US$ Mn) Forecast, 2023-2031
Figure 18: Europe Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 19: Europe Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 20: Europe Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 21: Europe America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 22: Europe Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 23: Europe Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
Figure 24: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, 2023-2031
Figure 25: Asia Pacific Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Asia Pacific Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 27: Asia Pacific Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 28: Asia Pacific America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 29: Asia Pacific Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 30: Asia Pacific Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
Figure 31: Latin America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
Figure 32: Latin America Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Latin America Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Latin America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 35: Latin America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 36: Middle East & Africa Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 37: Middle East & Africa Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Middle East & Africa America Women's Health Market Value Share Analysis, by Treatment Type, 2023-2031
Figure 39: Middle East & Africa America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 40: Middle East & Africa Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 41: Middle East & Africa Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
Figure 42: Global Women's Health Market Share Analysis, by Company (2022)

Women's Health Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Description

Table of Contents

List of Tables

Women's Health Market - Scope of Report

Key Questions Answered in Global women's health Market Report:

Women's Health Market - Research Objectives and Research Approach

Table of Contents

1. Executive Summary

2. Assumptions and Research Methodology

3. Executive Summary: Global Women's Health Market

4. Market Overview

5. Key Insights

6. Women's Health Market Analysis and Forecast, by Treatment Type

7. Global Women's Health Market Analysis and Forecast, by Disease Indication

8. Global Women's Health Market Analysis and Forecast, by Region

9. North America Women's Health Market Analysis and Forecast

10. Europe Women's Health Market Analysis and Forecast

11. Asia Pacific Women's Health Market Analysis and Forecast

12. Latin America Women's Health Market Analysis and Forecast

13. Middle East & Africa Women's Health Market Analysis and Forecast

14. Competition Landscape

List of Tables

List of Figures